Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-EN Version v3-EN
Language English English
Date Updated 2021-11-26 2021-09-08
Drug Identification Number 02142260 02142260
Brand name CLINIMIX CLINIMIX
Common or Proper name CLINIMIX 5% Amino Acids (Blend C) without Electrolytes in 16.6% Dextrose Injection CLINIMIX 5% Amino Acids (Blend C) without Electrolytes in 16.6% Dextrose Injection
Company Name BAXTER CORPORATION BAXTER CORPORATION
Ingredients LYSINE L-PHENYLALANINE L-LEUCINE DEXTROSE L-TYROSINE GLYCINE SERINE L-PROLINE L-ARGININE L-ALANINE TRYPTOPHAN L-THREONINE HISTIDINE L-VALINE L-ISOLEUCINE METHIONINE LYSINE L-PHENYLALANINE L-LEUCINE DEXTROSE L-TYROSINE GLYCINE SERINE L-PROLINE L-ARGININE L-ALANINE TRYPTOPHAN L-THREONINE HISTIDINE L-VALINE L-ISOLEUCINE METHIONINE
Strength(s) 290MG 280MG 365MG 16.6G 20MG 515MG 250MG 340MG 575MG 1.04G 90MG 210MG 240MG 290MG 300MG 200MG 290MG 280MG 365MG 16.6G 20MG 515MG 250MG 340MG 575MG 1.04G 90MG 210MG 240MG 290MG 300MG 200MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 2000 mL (JJ7770P) 2000 mL (JJ7770P)
ATC code B05BA B05BA
ATC description I.V. SOLUTIONS I.V. SOLUTIONS
Reason for shortage Demand increase for the drug. Shortage of an active ingredient.
Anticipated start date 2021-09-07 2021-09-07
Actual start date 2021-09-07 2021-09-07
Estimated end date 2021-11-25 Unknown
Actual end date 2021-11-25
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order. Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order.
Health Canada comments